Key Considerations of Balancing Investor Relations in Biotech
Hunter Smith, CFO of Rhythm Pharmaceuticals, discussed the importance of balance between investor expectations and long-term biotech priorities.
When asked about key considerations for balancing investor relations with clinical and scientific priorities, Smith replied:
So first and foremost is you should try to align yourself with anchor investors who truly understand the industry, truly understand your science and your clinical and regulatory opportunity, and truly have a long term view of the potential for value creation.
Smith emphasized the need for investors who have a long-term perspective, recognizing that success and failure are not always immediately rewarded or penalized by Wall Street.
- Align with anchor investors who understand the industry and science
- Have a long-term view of value creation
- Recognize that growth paths are rarely linear and involve luck
Author's summary: Balancing investor relations and biotech priorities requires careful consideration.